Patent http pat amgen com corlanor?

See the DrugPatentWatch profile for corlanor

What is the main patent protecting Corlanor?
Corlanor (trandolapril) is covered by a portfolio of patents that secure its active ingredient, the salt formulation, and specific dosing regimens. The core patents were filed in the early 2000s and are held by Amgen, the commercial sponsor of the drug.[1]

How long is the patent protection for Corlanor?
The key composition‑of‑matter and method‑of‑use patents expire in the early 2028 timeframe. Because patent terms are capped at 20 years from filing, the expiration dates line up with the original application dates from the early 2000s.[1]

Are there any challenges to Corlanor's patent?
Publicly known litigation has not targeted Corlanor’s patents. No major challenges or injunctions have been reported, and the patents remain in force until their scheduled expiration.[1]

Can biosimilars enter the market for Corlanor?
Biosimilars are not relevant for Corlanor, which is a small‑molecule drug. Generic competitors may enter after the patents expire, but the company’s exclusivity is likely to prevent generic entry until at least 2028.[1]

Who owns the patents for Corlanor?
Amgen retains ownership of all current patents covering Corlanor. The company continues to monitor and enforce its intellectual property rights in the United States and abroad.[1]

What does the patent say about pricing?
Patent protection allows Amgen to maintain a market‑exclusive pricing strategy. The exclusivity period extends the ability to set higher prices without generic competition until the patents lapse.[1]

When does exclusivity expire for Corlanor?
Exclusivity ends with the last patent in the portfolio, expected around 2028. After that, other manufacturers can apply to register generic versions of trandolapril in the U.S. market.[1]

Sources
[1] DrugPatentWatch.com – Corlanor patent details and status.